Quality of Life Research

, Volume 23, Issue 2, pp 561–570 | Cite as

Development and initial psychometric evaluation of the hepatitis C virus-patient-reported outcomes (HCV-PRO) instrument

  • Roger T. Anderson
  • Robert W. Baran
  • Birgitta Dietz
  • Eric Kallwitz
  • Pennifer Erickson
  • Dennis A. Revicki
Article

Abstract

Background

Chronic hepatitis C virus (HCV) infection is an important public health issue owing to its worldwide prevalence and its profound effects on patients’ well-being and function. We developed a new patient self-report tool, the HCV patient-reported outcomes (HCV-PRO) instrument, to assess patients’ function and well-being reflecting both HCV disease and treatment burdens.

Methods

Items were developed through a qualitative phase including scientific literature review, expert appraisal, and semi-structured patient interviews. The item pool was initially psychometrically tested in 60 adult HCV patients, 18 years of age or older at a university hepatology clinic. A final psychometric test was conducted in 241 members of the online Harris International Panel to examine scale reliability, confirm factor structure, and assess convergent and discriminant validity.

Results

A single-factor 16-item HCV-PRO instrument demonstrated good model fit. The HCV-PRO items and total score (range 0–100) showed excellent item response (few floor and ceiling effects) and reliability (alpha > 0.90). Convergent validity was established from moderate to high (r > 0.50) correlation with symptom burden, life satisfaction (ladder of life), and SF-36v2 scales scores. Mean HCV-PRO scores differentiated between currently treated patients, those previously treated, and patients never treated (p < 0.01), suggesting strong known-groups validity.

Conclusions

The results provide initial evidence that the HCV-PRO can yield reliable and valid measurement of the effects of HCV and its treatment on the well-being and function of HCV-infected patients.

Keywords

Psychometric methods Questionnaires Health status Quality of life 

Notes

Acknowledgments

Medical writing and editing services were provided by Amanda Perry, BA Palmyra PA, and Fabian Camacho MS Hershey PA for statistical support. Medical writing support was funded by Abbott Laboratories Inc., Abbott Park, Illinois.

References

  1. 1.
    World Health Organization. (2012). Hepatitis C. Fact Sheet N°164. Geneva, Switzerland: World Health Organization. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed 17 Sept, 2012.
  2. 2.
    Davis, G. L., Alter, M. J., El-Serag, H., Poynard, T., & Jennings, L. W. (2010). Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology, 138, 513–521.PubMedCrossRefGoogle Scholar
  3. 3.
    Ware, J. E, Jr, Bayliss, M. S., Mannocchia, M., & Davis, G. L. (1999). Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. The Interventional Therapy Group. Hepatology, 30, 550–555.PubMedCrossRefGoogle Scholar
  4. 4.
    Bayliss, M. S., Gandek, B., Bungay, K. M., Sugano, D., Hsu, M. A., & Ware, J. E, Jr. (1998). A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Quality of Life Research, 7, 39–55.PubMedCrossRefGoogle Scholar
  5. 5.
    Gremion, C., & Cerny, A. (2005). Hepatits C virus and the immune system: A concise review. Reviews in Medical Virology, 15, 235–268.PubMedCrossRefGoogle Scholar
  6. 6.
    Hsu, P., & Federico, C. A. (2012). Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. Journal of Gastroenterology and Hepatology, 27, 149–157.PubMedCrossRefGoogle Scholar
  7. 7.
    Younossi, Z., Kallman, J., & Kincaid, J. (2007). The effects of HCV infection and management on health-related quality of life. Hepatology, 45, 806–816.PubMedCrossRefGoogle Scholar
  8. 8.
    Smith, B. D., Morgan, R. L., Beckett, G. A., et al. (2012). Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recommendations and Reports 61(No. RR-4): 1–36.Google Scholar
  9. 9.
    Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009). Diagnosis, management, and treatment of hepatitis C: An update. Hepatology, 49, 1335–1374.PubMedCrossRefGoogle Scholar
  10. 10.
    National Institutes of Health. (2002). National institutes of health consensus development conference statement. Management of hepatitis C: 2002. NIH Consensus Development Program. http://consensus.nih.gov/2002/2002hepatitisc2002116html.htm. Accessed 20 Sept 2012.
  11. 11.
    Modi, A. A., & Liang, T. J. (2008). Hepatitis C: A clinical review. Oral Diseases, 14(1), 10–14.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Siebert, U., & Sroczynski, G. (2005). Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: A health technology assessment commissioned by the German federal ministry of health and social security. International Journal of Technology Assessment in Health Care, 21(1), 55–65.Google Scholar
  13. 13.
    Younossi, Z. M., Aggarwal, J., Martin, M., et al. (2012). Health-related quality-of-life among genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment: Post hoc analyses of data from the ADVANCE trial. Journal of Hepatology, 56(Suppl 2), S462–S463.CrossRefGoogle Scholar
  14. 14.
    Younossi, Z. M., Aggarwal, J., Martin, M., et al. (2012b). Health-related quality-of-life among genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment: Post hoc analyses of data from the ADVANCE trial. Gastroenterology 142(Suppl 5): S-955. [Abstract Sa1048].Google Scholar
  15. 15.
    Welsch, C., Jesudian, A., Zeuzem, S., & Jacobson, I. (2012). New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut, 61(suppl 1), i36–i46.PubMedCrossRefGoogle Scholar
  16. 16.
    Food and Drug Administration. (2009). Guidance for industry on patient-reported outcome measures: Use in medical product development to support labeling claims. Federal Register, 74, 65132–65133.Google Scholar
  17. 17.
    Guest, G., Bunce, A., & Johnson, L. (2006). How many interviews are enough? An experiment with data saturation and variability. Field Methods, 18(1), 59–82.CrossRefGoogle Scholar
  18. 18.
    Shumaker, S. A., Berzon, R., & Hays, R. (Eds.). (1993). Special issue. International use, application and performance of health-related quality of life instruments. Quality of Life Research, 2(6), 367–368.Google Scholar
  19. 19.
    Brod, M., Tesler, L. E., & Christensen, T. L. (2009). Qualitative research and content validity: Developing best practices based on science and experience. Quality of Life Research, 18, 1263–1278.PubMedCrossRefGoogle Scholar
  20. 20.
    Ware, J. E, Jr, Kosinski, M., Bjorner, J. B., Turner-Bowker, D. M., Gandek, B., & Maruish, M. E. (2007). User’s manual for the SF-36v2 health survey (2nd ed.). Lincoln: Quality Metric Incorporated.Google Scholar
  21. 21.
    Cantril, H. (1965). The pattern of human concerns. New Brubswick: Rutgers University Press.Google Scholar
  22. 22.
    Spiegel, B. M., Younossi, Z. M., Hays, R. D., Revicki, D., Robbins, S., & Kanwal, F. (2005). Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. Hepatology, 41, 790–800.PubMedCrossRefGoogle Scholar
  23. 23.
    Hollander, A., Foster, G. R., & Weiland, O. (2006). Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scandinavian Journal of Gastroenterology, 41(5), 577–585.PubMedCrossRefGoogle Scholar
  24. 24.
    Bernstein, D., Kleinman, L., Barker, C. M., Revicki, D. A., & Green, J. (2002). Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology (Baltimore, Md.), 35(3), 704–708.CrossRefGoogle Scholar
  25. 25.
    Mathews, A., Peiffer, L. P., Rhoades, K., & McGarrity, T. J. (2006). Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin. Health and Quality of Life Outcomes, 4, 30.CrossRefGoogle Scholar
  26. 26.
    Kang, S.-C., Hwang, S.-J., Lee, S.-H., Chang, F.-Y., & Lee, S.-D. (2005). Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan. World Journal of Gastroenterology: WJG, 11(47), 7494–7498.PubMedGoogle Scholar
  27. 27.
    Hassanein, T., Cooksley, G., Sulkowski, M., et al. (2004). The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. Journal of Hepatology, 40(4), 675–681.PubMedCrossRefGoogle Scholar
  28. 28.
    Nunnally, J. C., & Berstain, I. H. (1994). Psychometric theory (3rd ed.). New York: McGraw-Hill.Google Scholar
  29. 29.
    Wiggins, J. S. (1973). Personality and prediction: Principles of personality assessment. Reading, MA: Addison-Wesley.Google Scholar
  30. 30.
    MacCallum, R. (1986). Specification searches in covariance structure analysis. Psychological Bulletin, 100, 107–210.CrossRefGoogle Scholar
  31. 31.
    Bentler, P., & Bonnett, D. (1980). Significance tests and goodness of fit in the analysis of covariance structures. Psychological Bulletin, 88, 588–606.CrossRefGoogle Scholar
  32. 32.
    Bentler, P. (1990). Comparative fit indices in structural models. Psychological Bulletin, 107, 238–246.PubMedCrossRefGoogle Scholar
  33. 33.
    Bonkovsky, H. L., & Woolley, J. M. (1999). Consensus interferon study group. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology, 29, 264–270.PubMedCrossRefGoogle Scholar
  34. 34.
    Gralnek, I. M., Hays, R. D., Kilbourne, A., Rosen, H. R., Keeffe, E. B., Artinian, L., et al. (2000). Development and evaluation of the liver disease quality of life instrument in persons with advanced, chronic liver disease: The LDQOL 1.0. American Journal of Gastroenterology, 95(12), 3552–3565.PubMedGoogle Scholar
  35. 35.
    Shumaker, S. A., Anderson, R. T., & Czajkowski, S. M. (1990). Psychological tests and scales. In B. Spilker (Ed.), Quality of life assessments in clinical trials (pp. 95–114). New York: Raven Press.Google Scholar
  36. 36.
    Kleinman, L., Mannix, S., Yuan, Y., Kummer, S., L’Italien, G., & Revicki, D. (2012). Review of patient-reported outcome measures in chronic hepatits C. Health and Quality of Life Outcomes, 10, 92.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Roger T. Anderson
    • 1
  • Robert W. Baran
    • 2
  • Birgitta Dietz
    • 3
  • Eric Kallwitz
    • 4
  • Pennifer Erickson
    • 5
  • Dennis A. Revicki
    • 6
  1. 1.Department of Public Health SciencesPennsylvania State UniversityHersheyUSA
  2. 2.Global Health Economics & Outcomes ResearchAbbott LaboratoriesAbbott ParkUSA
  3. 3.Abbott GmbH & Co.LudwigshafenGermany
  4. 4.Division of HepatologyLoyola University Medical CenterMaywoodUSA
  5. 5.Pennsylvania State University and OLGAState CollegeUSA
  6. 6.Outcomes ResearchUnited BioSource CorporationBethesdaUSA

Personalised recommendations